Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

Moderna (MRNA) closed the most recent trading day at $66.98, moving -1.89% from the previous trading session. This change lagged the S&P 500's daily loss of 0.79%. On the other hand, the Dow ...

Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in ...

The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market ...

July 9 (Reuters) - Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Moderna (MRNA) climbed to $81.42, up 169% annually. Analysts set average target at $37 while insiders sold $6.1M worth of ...

Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In a ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

Global health organisation CEPI will give roughly $60 million to Moderna and two other groups to accelerate the development of shots ​against Ebola Bundibugyo, the deadly virus that has swept through ...